New patterns of HIV-1 resistance during HAART

Clinical Microbiology and Infection

Volumn 9, Issue 11, 2003, Pages 1077-1084

  Fumero, E ^a   Podzamczer, D ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Antiretrovirals; HIV resistance; Mutational patterns

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CROSS RESISTANCE; DRUG MECHANISM; DRUG RESPONSE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IMMUNE RESPONSE; INDIVIDUALIZATION; PHENOTYPE; PRIORITY JOURNAL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0242539778     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2003.00730.x     Document Type: Article

References (59)

1. Durant J, Clevenbergh P, Garraffo R et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the VIRADAPT study. AIDS 2000; 14: 1333-9.
2. Telenti A, Aubert V, Spertini F. Individualising HIV treatment - pharmacogenetics and immunogenetics. Lancet 2002; 359: 722-3.
3. Elbeik T, Hoo BS, Campodonico ME et al. In vivo emergence of drug-resistant mutations at less than 50 HIV-1RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from HIV-1 infected patients on HAART. J Hum Virol 2001; 4: 317-28.
4. Durant J, Clevenbergh P, Halfon P et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195-9.
5. Baxter JD, Mayers DL, Wentworth DN et al. A randomised study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000; 14: F83-92.
6. Cohen C, Keisser H, Hunt S et al. Phenotypic resistance testing significantly improves response to therapy: final analysis of a randomised trial (VIRA3001). Antiviral Ther 2000; 5: 67.
7. Meynard JL, Vray M, Morand-Joubert L et al. Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: a randomised trial (NARVAL, ANRS 088). Antiviral Ther 2000; 5: 67-8.
8. Pozniak AL, Gilleece Y, Nelson M et al. Zidovudine genotypic and phenotypic resistance arising in patients never exposed to zidovudine. Antiviral Ther 2000; 5: 42.
9. Ross LL, Fisher R, Scarsella A et al. Patients failing on d4T-based therapies that have developed thymidine analogue mutations; multidrug resistance or V75T mutations have reduced phenotypic susceptibiity to stavudine. Antiviral Ther 2000; 5: 38-9.
10. Costagliola D, Descamps D, Calvez V et al. Presence of thymidine analogue mutations and virologic response to non-nucleoside reverse transcriptase inhibitors. Antiviral Ther 2001; 6: S8.
11. Demeter LM, Nawatz T, Murse G et al. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy. J Infect Dis 1995; 172: 1480-5.
12. Boyer PL, Srafianos SG, Arnold E et al. Mechanisms of nucleoside analogue resistance [abstract 27]. Antiviral Ther 2002; 7: S25.
13. Meyer PR, Matsuura SE, So AG et al. A mechanism of ZDV resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999; 4: 35-43.
14. Meyer PR, Pfeifer P, Matsuura S et al. Effects of M41L and T215Y mutations in HIV-1 reverse transcriptase on removal of chain terminators from blocked primer/templates. Antiviral Ther 2000; 5: 14.
15. Ross L, Liao Q, Henry K et al. Choice of conucleoside analogue in d4T-treated subjects may influence the pattern of thymidine analogue mutations (TAMs) and multi-nucleoside resistant mutations (MRM) [abstract 568-T]. In: 9th Conference on Retroviruses and Opportunistic Infections, Seattle. Alexandria, VIA: Foundation for Retrovirology and Human Health, 2002: 263.
16. Kuritzkes D, Bassett RL, Young RK et al. Rate of emergence of thymidine-resistant analogue mutations in HIV-1 selected by stavudine or zidovudine based regimens in treatment naive patients [abstract 36]. Antiviral Ther 2002; 7: S31.
17. Deluguerre C, Mouroux M, Yvon-Groussin A et al. Epidemiology and conditions of selection of 44D/A and/or 118I reverse transcriptase mutations in 344 patients. Antiviral Ther 2000; 5: 18-19.
18. Girouard M, Diallo K, Marchand M et al. The V118I mutation in the reverse transcriptase of HIV-1 diminishes the incorporation of multiple nucleoside analogue inhibitors [abstract 26]. Antiviral Ther 2002; 7: S24.
19. Ait-Khaled M, Rakik A, Griffin P et al. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1 infected adults with no prior antiretroviral therapy. Antiviral Ther 2002; 7: 43-51.
20. Opravil M, Yerly S, Stazewsky S et al. Prior treatment with mono or dual NRTIs before HAART as predictor of virologic failure in simplified abacavir-based triple NRTI regimen: results from the Simplified Maintenance Trial (SMT) and 30017. Antiviral Ther 2000; 5: 95-6.
21. Dalmau D, Ochoa de Echaguen A, Martinez E et al. NEFA simplification trial: patterns of resistance mutations among patients with virological failure. Antiviral Ther 2002; 7: S113.
22. Tian H, Whitcomb JM, Limli K et al. Zidovudine/ lamivudine resistance is preceded by a transient period of zidovudine hypersensitivity. Antiviral Ther 1998; 3: 22-3.
23. Iversen AK, Shaffer RW, Wehrly K et al. Multidrug-resistant HIV-1 strains resulting from combination antiretroviral therapy. J Virol 1996; 70: 1086-90.
24. Shafer RW, Kozal MJ, Winters M et al. Combination therapy with zidovudine and didanosine selects for drug-resistant HIV-1 strains with unique patterns of pol gene mutations. J Infect Dis 1994; 169: 722-9.
25. Miller MD, Margot NA, Hertgs K et al. Antiviral activity of tenofovir against nucleoside-resistant HIV samples [abstract 2115]. In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto. Washington DC: American Society for Microbiology, 2000: 350.
26. Tamalet C, Yahi N, Tourres C et al. A unique molecular mechanism of resistance to multiple dideoxynucleosides provided by MDR mutations and insertions/deletions in HIV-1 reverse transcriptase gene. Antiviral Ther 2000; 5: 20.
27. Tuske S, Sarafianos S, Clark AD et al. Crystal structure of HIV-1 RT with template-primer terminated with the acyclic nucleotide RT inhibitor tenofovir suggests mechanisms of evading resistance [abstract 44]. In: 9th Conference on Retroviruses and Opportunistic Infections, Seattle. Alexandria, VA: Foundation for Retrovirology and Human Health, 2002: 68.
28. Miller MD, Margot NA, Lu B et al. Effect of baseline nucleoside-associated resistance on response to tenofovir DF therapy. Integrated analyses of studies 902 and 907 [abstract 43]. In: 9th Conference on Retroviruses and Opportunistic Infections, Seattle. 2002.
29. D'Aquila RT, Shapiro J, Brun-Vézinet F et al. Drugs mutations in HIV-1. Topics HIV Med 2002; 10: 11-15.
30. Huang W, Wrin T, Gamarink A et al. Reverse transcriptase mutations that confer non-nucleoside reverse transcriptase inhibitor resistance may also impair replication capacity [abstract 72]. Antiviral Ther 2002; 7: S60.
31. Casado JL, Moreno A, Hertogs K et al. Early switch from nevirapine to efavirenz suggested for HIV salvage therapy. AIDS Res Hum Retroviruses 2002; 18: 771-5.
32. Gallant J. Therapy for the treatment-experienced patient. Hopkins HIV Rev 1999; 11: 14-15.
33. Harrigan PR, Salim M, Stammers DK et al. A mutation in the 3′ region of the HIV-1 RT (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance. J Virol 2002; 76: 6836-40.
34. Haubrich R, Hellmann N, Keiser P et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis [abstract ThOrB1388]. In: XIV International AIDS Conference, Barcelona. Barcelona: Prous Science, S.A., 2002: 377.
35. Robbins G, Shafer R, Smeaton L et al. Antiretroviral strategies in naive HIV subjects: comparison of sequential 3-drug regimens (ACTG 384) [abstract LbOr20A]. In: XIV International AIDS Conference, Barcelona. Barcelona: Prous Science, S.A., 2002: 377. Program Supplement, 26.
36. Shulman N, Zolopa A, Passaro D et al. Phenotypic hypersusceptibility in non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS 2001; 115: 1125-32.
37. Mellors J, Vaida F, Bennet K et al. Efavirenz hypersusceptibility improves virologic response to multidrug salvage regimens in ACTG 398 [abstract 45]. In: 9th Conference on Retroviruses and Opportunistic Infections, Seattle. Alexandria, VA: Foundation for Retrovirology and Human Health, 2002: 69.
38. Sankatsing S, Weverling G, van't Klooster G et al. TMC125 monotherapy for 1 week results in a similar initial rate of decline of HIV-1 RNA as therapy with a 5-drug regimen [abstract 5]. In: 9th Conference on Retroviruses and Opportunistic Infections, Seattle. Alexandria, VA: Foundation for Retrovirology and Human Health, 2002: 54.
39. Vingerhoets J, Azjin H, Fransen E et al. TMC 125 can suppress the selection of resistant HIV from a virus population carrying the K103N or Y181C mutation. Antiviral Ther 2002; 7: S8.
40. Clotet B, Ruiz L, Martinez-Picado J et al. Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts. HIV Clin Trials 2002; 3: 316-23.
41. Martinez-Picado J, Savara AV, Sutton L et al. Replicative fitness of protease inhibitor-resistant mutants of HIV-1. J Virol 1999; 73: 3744-52.
42. Xu R, Andrew W, Spalstestein A et al. Molecular mechanisms of I50V HIV-1 protease resistance and cross-resistance to protease inhibitors [abstract 563-T]. In: 9th Conference on Retroviruses and Opportunistic Infections, Seattle. Alexandria, VA: Foundation for Retrovirology and Human Health, 2002: 62.
43. Maguire M, Guinea R, Griffin P et al. Changes in HIV type 1 Gag at positions L449 and P453 are linked to 150V protease mutant in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol 2002; 76: 7398-406.
44. Maguire M, Shortino D, Klein A et al. Emergence of resistance to protease inhibitor amprenavir in HIV1: selection of four alternative viral protease genotypes ad influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother 2002; 46: 731-8.
45. Prado JG, Wrin T, Beauchaine J et al. Amprenavir-resistant-HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 2002; 16: 1009-17.
46. Hsu A, Kempf D, Granneman R et al. Exploring theorical mechanisms for lack of resistance to lopinavir/ritonavir in antiretroviral naive subjects [abstract 436-W]. In: 9th Conference on Retroviruses and Opportunistic Infections, Seattle. Alexandria, VA: Foundation for Retrovirology and Human Health, 2002: 217.
47. Kempf D, Isaacson J, King MS et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduce susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75: 7462-9.
48. Isaacson J, Kempf D, Calvez V et al. Quantitative estimate of the effect of individual baseline mutations in HIV protease on the virologic response to lopinavir/ritonavir therapy in heavily experienced patients [abstract 559-T]. In: 9th Conference on Retroviruses and Opportunistic Infections, Seattle. Alexandria, VA: Foundation for Retrovirology and Human Health, 2002: 260.
49. Masquelier B, Breihl D, Neau D et al. Human immunodeficiency virus type-1 genotypic and pharmacokinetics determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother 2002; 46: 2926-32.
50. Piliero PJ. Atazanavir: a novel HIV-1 protease inhibitor. Expert Opin Invest Drugs 2002; 11: 1295-301.
51. Colonno RJ, Friborg J, Rose RE et al. Identification of amino acid substitutions correlated with reduced atazanavir susceptibility in patients treated with atazanavir-containing regimens [abstract 4]. Antiviral Ther 2002; 7: S4.
52. Curry R, Markowitz M, Slater L, Mayers D et al. Safety and efficacy of tipranavir, a non-peptidic protease inhibitor, in multiple PI-failure patients [abstract 3]. In: 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires. Buenos Aires: International Aids Society, 2001: 79.
53. Schwartz R, Kazanjian P, Slater L et al. Resistance to tipranavir is uncommon in a randomized trial of tipranavir/ritonavir in multiple PI-failure patients [abstract 562-T]. In: 9th Conference on Retroviruses and Opportunistic Infections, Seattle. Alexandria, VA: Foundation for Retrovirology and Human Health, 2002: 261.
54. McCallister S, Neubacher D, Verbiest W et al. Susceptibility profile of tipranavir at baseline and subsequent virologic response in a cohort of patients with multiple-PI failure. Anitviral Therapy 2002, 7: S105.
55. Doyon L, Tremblay S, Cartier M et al. In vitro susceptibility of HIV-1 to tipranavir. Antiviral Therapy, 2002, 7: S9.
56. Roman F, Gonzalez D, Boulme R et al. New mutations at residue positions critical to T-20 resistance in T-20 naive patients infected with clade B HIV-1 isolates [abstract 18]. Antiviral Ther 2002; 7: S14.
57. Mink M, Greenberg M, Mosier S et al. Impact of HIV-1 gp41 amino acid substitutions (positions 36-45) on susceptibility to T-20 (enfuvirtide) in vitro: analysis of primary virus isolates recovered from patients during chronic enfuvirtide treatment and site-directed mutants in NL4-3 [abstract 22]. Antiviral Ther 2002; 7: S17.
58. Kemp SD, Ruiz L, Lucas AM et al. Novel mutations in a highly conserved region of HIV-1 gp41 are associated with T-20 treatment [abstract 13]. Antiviral Ther 2002; 7: S11.
59. Hanna S, Yang C, Owen S et al. Resistance mutation in HIV entry inhibitors. AIDS 2002; 16: 1603-8.